Death during intensive glycemic therapy of diabetes: mechanisms and implications
PE Cryer - The American journal of medicine, 2011 - amjmed.com
Despite its documented microvascular 1-3 and potential macrovascular 4, 5 benefits in both
type 1 and type 2 diabetes mellitus, intensive glycemic therapy was not found to produce
macrovascular benefits, let alone survival benefits, in 3 recent randomized clinical trials:
Action to Control Cardiovascular Risk in Diabetes (ACCORD), 6 Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation
(ADVANCE), 7 and Veterans Affairs Diabetes Trial (VADT). 8 Similarly, it was not found to …
type 1 and type 2 diabetes mellitus, intensive glycemic therapy was not found to produce
macrovascular benefits, let alone survival benefits, in 3 recent randomized clinical trials:
Action to Control Cardiovascular Risk in Diabetes (ACCORD), 6 Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation
(ADVANCE), 7 and Veterans Affairs Diabetes Trial (VADT). 8 Similarly, it was not found to …